SCHIMMEL PAUL purchased 242.1% of their position (1M shares) of ATYR PHARMA INC on the open market
Open‑market purchase worth $911.8K — a major conviction buy. The strongest form of insider conviction signal.
P · 2 purchases
Filed: 10/9/2025ACC: 0001193125-25-236131
+1M
Net shares
Net buyer
$911.8K
Total acquired
2
Open market trades
2B · 0S
2
Total transactions
1M acquired
Non-Derivative Transactions2
Common Stock
Indirect
Shares
+682K
Price / share
$0.90
Trade value
$612.44K
% of position
165.1%
10/8/2025
413.02K→1.10M
Common Stock
Indirect
Shares
+318K
Price / share
$0.94
Trade value
$299.36K
% of position
29.0%
10/9/2025
1.10M→1.41M
Total
Net shares
+1M
Net value
$911.80K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 10/8/2025 | P · Purchase | +682K | $0.90 | $612.44K | 165.1% | 413.02K | 1.10M |
| Common Stock Indirect | 10/9/2025 | P · Purchase | +318K | $0.94 | $299.36K | 29.0% | 1.10M | 1.41M |
| Total | +1M | $911.80K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)2
Common Stock
IndirectShares owned679.14K
Common Stock
DirectShares owned8.89K
Total
8.89K direct·679.14K indirect688.03K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 679.14K | Indirect |
| Common Stock | 8.89K | Direct |
| Total | 688.03K | 8.89K direct·679.14K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported